Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 6, November-December, p. 1073–1078

Publication type: review article

Language: English

The Polymorphism of Paraoxonase and Its Effects in Physiological and Pathological Processes

Polimorfizm paraoksonazy a procesy fizjologiczne i patologiczne

Jowita Zielaskowska1,, Dorota Olszewska−Słonina1,

1 Department of Medical Biology, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland, Nicolaus Copernicus University, Toruń, Poland

Abstract

Paraoxonase PON1 (aryldialkylphosphatase, E.C.3.1.8.1) hydrolyzes toxic organophosphate compounds (paraxon, sarin), phospholipid hydroperoxides and cholesterol ester hydroperoxides. The high−density lipoprotein−associated enzyme, paraoxonase, prevents the oxidation of low−density lipoprotein by oxygen reactive forms. These mechanisms play a basic role in many pathological processes. PON1 exists in two polymorphic forms: R192Q and L55M. Both isoforms of PON influence metabolism and in prevention of coronary heart disease. Paraoxonase activity is regulated by genetical (polymorphism) and environmental factors (nicotine, diet, alcohol etc.). Highly conservative PON’s family is divided on three classes: PON1, PON2, PON3.

Streszczenie

Paraoksonaza PON1 (arylodialkilofosfataza, E.C.3.1.8.1) hydrolizuje toksyczne związki fosforoorganiczne (paraokson, sarin), nadtlenki fosfolipidowe oraz wodoronadtlenki estrów cholesterolu. W ludzkiej surowicy enzym PON1 jest związany z frakcją HDL. Rola enzymu PON1 polega na ochronie frakcji LDL przed utlenieniem przez reaktywne formy tlenu. Chroniąc frakcje LDL, PON1 zapobiega powstawaniu aterogennych cząsteczek oxLDL, a tym samym powstawaniu procesów patologicznych. PON1 występuje w dwóch polimorficznych formach: jako R192Q i L55M. Aktywność paraoksonazy jest regulowana czynnikami genetycznymi (polimorfizm) i środowiskowymi (nikotyna, dieta, alkohol itp.). Wysoko konserwatywna rodzina białek enzymatycznych PON dzieli się na trzy klasy: PON1, PON2 i PON3.

Key words

paraoxonase, oxidation of LDL

Słowa kluczowe

paraoksonaza, utlenione lipoproteiny

References (37)

  1. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35, 1126–38.
  2. Furlong CE, Richter RJ, Chapline C, Crabb JW: Purification of rabbit and human serum paraoxonase. Biochemistry 1991, 30, 10133–10140.
  3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7, 69–76.
  4. La Du BN, Adkins S, Kuo CL, Lipsig D: Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993, 87. 25–34.
  5. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001, 21, 1451–1457.
  6. Hegele RA, Brunt JH, Connelly PW: A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995, 15, 89–95.
  7. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999, 26, 892–904.
  8. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonky O, Meged R, Dvir H, Ravelli R, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS: Structure and evolution of the serum paraoxonase family of detoxifying and anti−atherosclerotic enzymes. Nat Struct Mol Biol 2004, 11, 5, 412–419.
  9. Primo−Parmo SL, Sorenson RC, Teiber J, La Du BN: The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33, 498–507.
  10. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3, 73–76.
  11. Kuo C−L, La Du BN: Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metabol Diopos 1998, 26, 653–660.
  12. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Arterioscler Thromb Vasc Biol 1998, 18, 1617–1624.
  13. Gotto AM Jr: High−density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002, 144, S33–42.
  14. Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52. 598–608.
  15. La Du BN: Structural and functional diversity of paraoxonases. Nat Med1996, 2, 1186–1187.
  16. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998, 423, 57–60.
  17. Agachan B, Yilmaz H, Isbir T, Akoglu E: Paraoxonase 192 polymorphism and its relationship to serum lipids in Turkish renal transplant recipients. Transplant Proc 2004, 36, 1385–1386.
  18. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21, 473–480.
  19. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA: Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001, 29, 566–569.
  20. Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998, 136, 217–223.
  21. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W: Expression of the peroxisome proliferator−activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Natl Acad Sci USA 1998, 95 (13), 7614–7619.
  22. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI: Hydrolysis of platelet−activating factor by human serum paraoxonase. Biochem J 2001, 354, 1–7.
  23. Nguyen SD, Sok DE: Effect of 3,4−dihydroxyphenylalanine on Cu(2+)−induced inactivation of HDL−associated paraoxonase and oxidation of HDL; inactivation of paraoxonase activity independent of HDL lipid oxidation. Free Radic Res 2004, 38: 969–976.
  24. Leviev I, James RW: Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000, 20, 516–521.
  25. Sanghera DK, Saha N, Aston CE, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997, 17, 1067–1073.
  26. Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T: Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case−control study. BMJ 1999, 319, 487–489.
  27. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE: Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002, 22, 1329–1333.
  28. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G: Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002, 132, 3012–3017.
  29. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB: Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003, 52, 1287–1294.
  30. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, Seppala, E, Matikainen M, Kallioniemi O, Schleutker J, Lehtimaki T, Salonen J: New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst 2003, 95, 812–818.
  31. Berry R, Schaid DJ, Smith JR French AJ, Schroeder JJ, McDonnell SK, Peterson BJ,Wang ZY, Carpten JD, Roberts SG, Tester DJ, Blute ML, Trent JM, Thibodeau SN: Linkage analyses at the chromosome 1 loci 1q24− 25 (HPC1), 1q42.2−43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000, 66, 539–546.
  32. Berthon P, Valeri A, Cohen−Akenine A: Predisposing gene for early−onset prostate cancer, localized on chromosome 1q42.2−43. Am J Hum Genet 1998, 62, 1416–1424.
  33. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA: Evidence for a rare prostate cancer – susceptibility locus at chromosome 1p36. Am J Hum Genet 1999, 64, 776–787.
  34. Rebbeck TR: Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000, 67, 1014–1019.
  35. Smith JR, Freije D, Carpten JD Gronberg H, Xu J, Isacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker−Daniels J, Bailey−Daniels J, Baailey−Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome−wide search. Science 1996, 274, 1371–1374.
  36. Xu J, Meyers D, Freije D: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20, 175–179.
  37. Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48, 261–268.